Addex Therapeutics Ltd American Depositary Shares (ADXN) Stock Price

ADXNStock

$3.84−50.34%52W

Market Cap$4.86M

P/E0.80x

PEG Ratio—

Div yield—

Beta0.01

ADXN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-51.93%

Price vs S&P 500 (4W)-29.54%

VGM Score24.77

P/E Ratio (Annual)0.80x

Book Value / Share (Quarterly)$0.03

P/TBV (Annual)1.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-50.73%

Cash Flow / Share (Quarterly)$-0.02

Price vs S&P 500 (YTD)-60.84%

Net Profit Margin (TTM)-6362.68%

EPS (TTM)$-0.08

10-Day Avg Trading Volume3.03M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)-46.32%

EPS (Annual)$-0.08

ROI (Annual)-140.13%

Gross Margin (Annual)-958.33%

Net Profit Margin (5Y Avg)-946.84%

Cash / Share (Quarterly)$0.01

Revenue Growth QoQ (YoY)-89.18%

P/E Normalized (Annual)0.80x

ROA (Last FY)-105.72%

Revenue Growth TTM (YoY)-82.97%

EBITD / Share (TTM)$-0.03

ROE (5Y Avg)-300.60%

Operating Margin (TTM)-2454.94%

Cash Flow / Share (Annual)$-0.02

P/B Ratio1.45x

P/B Ratio (Quarterly)2.57x

Net Income / Employee (Annual)$-4,163,269

EV / Revenue (TTM)35.90x

Net Interest Coverage (TTM)-0.70x

ROA (TTM)-103.37%

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)1.40x

Quick Ratio (Quarterly)0.79x

3-Month Avg Trading Volume0.48M

52-Week Price Return-50.34%

Revenue / Employee (TTM)$67,694

Tangible BV / Share (Quarterly)$0.05

P/S Ratio (Annual)27.56x

Asset Turnover (Annual)0.03x

52-Week High$0.11

Operating Margin (5Y Avg)-869.64%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)-46.31%

Tangible BV CAGR (5Y)10.45%

26-Week Price Return-40.00%

Quick Ratio (Annual)1.39x

13-Week Price Return-36.56%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)0.97x

Enterprise Value$4.87M

Revenue / Share Growth (5Y)-59.42%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-40.43%

Revenue / Employee (Annual)$106,925

Pretax Margin (Annual)-3958.46%

Cash / Share (Annual)$0.02

3-Month Return Std Dev91.05%

Gross Margin (5Y Avg)-178.93%

Net Income / Employee (TTM)$-4,311,157

ROE (Last FY)-141.15%

Net Interest Coverage (Annual)-0.61x

EPS Basic Excl Extra (Annual)$-0.08

Receivables Turnover (TTM)5.25x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)20.05x

ROI (TTM)-130.00%

P/S Ratio (TTM)43.51x

Pretax Margin (5Y Avg)-1445.86%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.05

Price vs S&P 500 (52W)-68.90%

Year-to-Date Return-48.01%

5-Day Price Return2.86%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-117.13%

Net Profit Margin (Annual)-3892.31%

Month-to-Date Return-31.43%

Cash Flow / Share (TTM)$-0.27

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-1628.25%

LT Debt / Equity (Annual)1.77x

ROI (5Y Avg)-251.39%

LT Debt / Equity (Quarterly)0.53x

EPS Basic Excl Extra (TTM)$-0.08

P/TBV (Quarterly)1.69x

P/B Ratio (Annual)1.69x

Pretax Margin (TTM)-6467.09%

Book Value / Share (Annual)$0.05

Price vs S&P 500 (13W)-38.52%

Beta0.01x

P/FCF (Annual)2.73x

Revenue / Share (TTM)$0.00

ROE (TTM)-131.30%

52-Week Low$0.03

vGradeD

gGradeF

mGradeD

vgmGradeD

ADXN Analyst Recommendations

Oct 2025

Nov 2025

Dec 2025

Jan 2026

2.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADXNAddex Therapeutics Ltd American Depositary Shares	D	F	D	$3.84
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Addex Therapeutics Ltd American Depositary Shares

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company specializing in the development of allosteric modulators, an emerging class of orally available small-molecule drugs. Operating from its base in Switzerland and Europe, the company focuses on the discovery, development, and commercialization of these novel therapeutics.